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 Multi drug resistance is for a lot of years still a big problem in therapy of cancer. 
Anthracycline antibiotics are highly efficient for treating cancers but multi drug resistance 
and severe side effects sometimes restrain the use of them and lead therapy to fail. One 
of the worst adverse effect is a cardiotoxicity. By older studies, the mechanism of a 
cardiotoxicity was because of formation of reactive oxygen species (ROS). Many times, 
the negative effects of ROS on cardiac muscle cells was confirmed but nowadays the 
evidence opens some other and more complex mechanisms of its damage. 
 The main point of this work was examination of enzymes which metabolize 
anthracyclines, mainly daunorubicin. Metabolites which are formed are less potent than 
parent drug and they have bigger toxicity. This can have an impact on therapy and can 
cause a cardiotoxicity. 
 In our study we used 3 inhibitors, midostaurin, vistusertib, talazoparib and we 
tested their inhibition potential on daunorubicin reducing enzymes AKR1A1, AKR1B10, 
AKR1C3, AKR7A2 and CBR1. On the base of our results, the most inhibited enzyme is 
AKR1C3, which is valid for all 3 inhibitors tested. Most efficient inhibitor for AKR1C3 
is midostaurin (93 % of inhibition with 50 µM). Inhibition of AKR1B10 is most efficient 
with vistusertib (38 % of inhibition with 50 µM). Others inhibit the enzyme only up to 18 
% with 50 µM. We have similar results with AKR1A1, for which the most efficient 
inhibitor is midostaurin (28 % of inhibition with 50 µM). The weakest inhibition is shown 
 
 
in AKR7A2 with maximal inhibition of 27 % with 50 µM of vistusertib. Other inhibitors 
show no efficiency against AKR7A2. We have not found a significantly potent inhibitor 
for CBR1. The highest inhibition of CBR1 was found for vistusertib (52 % of inhibition 
with 50 µM). 
 We finished this work by doing inhibition tests on cell line KG1a with 
midostaurin. By this test we confirmed higher cytotoxic effect of daunorubicin in 
presence with midostaurin.  
